Foghorn therapeutics to present preclinical data from its selective cbp and ep300 protein degrader programs and preclinical data for fhd-286, a potent, selective inhibitor of brg1 and brm, at the 2023 american association for cancer research annual meeting

Cambridge, mass., april 10, 2023 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that preclinical data from two of its protein degrader programs, selective ep300 and selective cbp, and preclinical data for its brg1/brm inhibitor, fhd-286, will be presented at the 2023 american association for cancer research (aacr) annual meeting. the meeting will be held april 14–19, 2023, in orlando, fl.
FHTX Ratings Summary
FHTX Quant Ranking